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S U M M A R Y
Objectives: The most common complication of herpes zoster (HZ) is postherpetic neuralgia (PHN), a
persistent pain that can substantially affect quality of life (QoL). This analysis aimed to evaluate
predictors of PHN in HZ patients.
Methods: A pooled analysis of prospective cohort studies of HZ patients aged 50 years from North
America (Canada), Latin America (Brazil, Mexico, and Argentina), and Asia (Taiwan, South Korea, and
Thailand) was performed. Patients within 14 days of rash onset were included. The incidence of PHN was
deﬁned as a worst pain score of 3, persisting/appearing at >90 days after rash onset. Socio-
demographics, HZ disease characteristics, treatment, pain-related interference with activities of daily
living, and health-related QoL were assessed.
Results: Of 702 patients with HZ, 148 (21.1%) developed PHN. Similar risks of PHN were observed across
geographic regions. On multivariate analysis, older age, greater severity of pain at rash onset,
employment status, walking problems at enrollment, and pain interference affecting social relationships
were signiﬁcantly associated with the development of PHN.
Conclusions: In addition to older age and severe acute pain, this study suggests that impaired physical
and social functioning from acute zoster pain may play a role in the development of PHN in this
prospective cohort study of HZ patients from North and Latin America and Asia.
 2015 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Herpes zoster (HZ) is caused by reactivation of the latent
varicella zoster virus (VZV) in sensory ganglia and is typically
characterized by painful, blistering rashes.1 The lifetime risk of HZ
is approximately 30%.2 For some patients, pain continues to persist* Corresponding author. Tel.: +1 617 869 2513.
E-mail address: kkawai8@gmail.com (K. Kawai).
http://dx.doi.org/10.1016/j.ijid.2015.03.022
1201-9712/ 2015 Published by Elsevier Ltd on behalf of International Society for Infect
creativecommons.org/licenses/by-nc-nd/4.0/).after the rash heals and develops into postherpetic neuralgia
(PHN). PHN is the most common complication of HZ and occurs in
approximately 5% to 30% of HZ patients.3 The risk of PHN increases
with age. PHN can persist for several months to several years, and
even up to 10 years. PHN substantially affects patient quality of life
(QoL) and can cause physical disability, emotional distress, and
social isolation.4 PHN patients experience different types of pain
including a steady burning pain, intermittent stabbing or shooting
pain, and stimulus-evoked pain (allodynia). Treatments for PHN
include anticonvulsants, topical lidocaine or capsaicin, tricyclicious Diseases. This is an open access article under the CC BY-NC-ND license (http://
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ment has limited efﬁcacy and patients are often refractory to these
treatments. As an effective preventive strategy, a live-attenuated
VZV vaccine (Zostavax by Merck) has been demonstrated to
signiﬁcantly reduce the risk of HZ and PHN.7
Understanding the predictors of PHN is important to enable
healthcare professionals to identify patients at risk of PHN who
might beneﬁt from early treatment. It may also help researchers to
better understand the pathophysiology of PHN. It is recognized
that older age, greater acute pain severity, and greater rash severity
increase the risk of developing PHN.6,8–23 However, other factors,
such as prodromal pain, female sex, and functional and psychoso-
cial status, have rarely been evaluated or have not been
consistently associated with the risk of PHN.8,11,15 Conﬂicting
results could be due to differences in the deﬁnition of PHN, study
population, and methodology. Furthermore, prior research has
been conducted mostly in North America and Europe, but less
frequently in other geographic regions.
The objective of this study was to evaluate the predictors of
PHN from a pooled analysis of prospective cohort studies of
patients with HZ from North America (Canada), Latin America
(Mexico, Brazil, and Argentina), and Asia (Taiwan, South Korea, and
Thailand).
2. Methods
2.1. Study design and population
Data from the MASTER study (Monitoring and Assessing
Shingles Through Education and Research), a prospective cohort
study of patients with HZ conducted in seven countries (Canada,
Brazil, Mexico, Argentina, Taiwan, South Korea, and Thailand)
using the same methodology, were pooled.20,24–28 Eligible
participants were patients with a physician-conﬁrmed diagnosis
of HZ rash or zoster-associated pain with documented date of rash
onset in the medical chart, 50 years of age, and capable of
completing the study questionnaires. Patients were recruited at
different time points during the course of their disease. However,
the current analysis was restricted only to patients enrolled within
14 days of rash onset. Patients were followed prospectively for
6 months to assess their zoster-associated burden of illness,
including severity and duration of pain, impact on health-related
QoL, and healthcare utilization. All participants signed an informed
consent form prior to any study-related procedure. The study was
approved by local institutional review boards in each country.
2.2. Deﬁnition of postherpetic neuralgia
The incidence of PHN was deﬁned as a worst pain score of 3,
persisting or appearing more than 90 days after the onset of rash. A
previous validation study has shown that worst pain scores of 3
occurring 90 days after rash onset signiﬁcantly impair QoL and
activities of daily living.29 This deﬁnition was used in a clinical trial
of zoster vaccination and other studies.7
2.3. Assessment
A physician reviewed the patient’s characteristics of HZ and
treatment at the time of recruitment. To assess zoster-associated
pain and its impact on activities of daily living from the patient’s
perspective, the Zoster Brief Pain Inventory (ZBPI) and the Initial
Zoster Impact Questionnaire (IZIQ) were used. The ZBPI is a
validated self-administered questionnaire that assesses the
severity of pain associated with HZ using a scale from 0 (no pain)
to 10 (pain as bad as you can imagine).29 The ZBPI also assesses the
interference of pain with daily activities, including general activity,mood, walking ability, normal work, relations with other people,
sleep, and enjoyment of life.
The following socio-demographics, characteristics of HZ, and
health indicators were evaluated as potential predictors of PHN:
age, sex, level of education, employment status, living alone,
immune status, presence of other pain conditions, and pre-existing
problems in the EQ-5D ﬁve health domains. The following HZ
characteristics were also examined as predictors: severity of rash
(number of lesions), worst pain score at rash onset, prodromal pain
(duration and severity of pain), problems in EQ-5D health domains
at rash onset, pain interference with daily activities at rash onset,
and use of antiviral medications.
2.4. Statistical analysis
Baseline characteristics of HZ patients by PHN status were
compared using the Chi-square test or Fisher’s exact test, as
appropriate, for categorical variables. To examine factors associat-
ed with the risk of developing PHN, binomial regression models
were used with a log-link function and computed risk ratio (or
relative risk, RR) and associated 95% conﬁdence intervals (CI). The
parsimonious multivariate regression model was built using a
backward selection procedure. Variables with p < 0.20 in the
univariate analysis were considered as candidates for the
multivariate model, and variables with p < 0.05 were kept in
the ﬁnal model.
3. Results
A total of 702 patients with HZ were included in the analysis
(Table 1). Approximately 38% of participants were aged 50–59
years, 31% were aged 60–69 years, and 31% were aged 70 years.
The majority of patients were women (62%), and 32% reported
being employed. The baseline clinical characteristics of HZ disease
were generally comparable across the three geographic regions.
About 58% of patients reported a severe worst pain score at rash
onset (7). The majority of patients reported taking antiviral
medications (87%).
Of 702 patients with HZ, 148 (21.1%) developed PHN. The age-
speciﬁc risk of PHN ranged from 14.0% in adults 50–59 years of age
and 20.6% in adults 60–69 years of age, to 29.7% in adults 70 years
of age. In the univariate analysis, older age, employment status,
greater severity of pain at rash onset, severe prodromal pain,
problems in health domains in the EQ-5D at enrollment (except
being anxious or depressed), and reported pain interference from
acute HZ on activities of daily living (all seven items of ZBPI) were
signiﬁcantly associated with an increased risk of PHN (Table 2). No
signiﬁcant differences in the risk of PHN were found by geographic
region, sex, level of education, living alone, immune status,
presence of other pain conditions, pre-existing problems in the EQ-
5D health domains, severity of rash, or use of antiviral medications
during the acute phase.
In the multivariable regression model (Table 3), older age (60–
69 vs. 50–59 years, RR 1.20, 95% CI 0.81–1.79; 70 vs. 50–59 years,
RR 1.72, 95% CI 1.18–2.51), greater severity of pain at rash onset
(moderate vs. no/mild, RR 2.46, 95% CI 0.91–6.66; severe vs. no/
mild RR 3.58, 95% CI 1.36–9.45), employment status (RR 0.58, 95%
CI 0.38–0.89), walking problems at enrollment (RR 1.47, 95% CI
1.11–1.93), and pain interference affecting relationships with
other people (RR 1.69, 95% CI 1.27–2.25) were signiﬁcantly
associated with the development of PHN.
4. Discussion
The risk of developing PHN, deﬁned as a pain score of 3 lasting
or appearing more than 90 days after rash onset, was approximately
Table 1
Baseline characteristics











Age, years, n (%)
50–59 147 (43.4%) 33 (25.2%) 84 (36.4%) 264 (37.7%)
60–69 110 (32.4%) 44 (33.6%) 64 (27.7%) 218 (31.1%)
70 82 (24.2%) 54 (41.2%) 83 (35.9%) 219 (31.2%)
Sex, n (%)
Female 205 (60.5%) 87 (66.4%) 140 (60.6%) 432 (61.6%)
Male 134 (39.5%) 44 (33.6%) 91 (39.4%) 269 (38.4%)
Level of education, n (%)
Primary/grade school 128 (38.6%) 63 (48.1%) 32 (14.0%) 223 (32.3%)
High school 120 (36.1%) 27 (20.6%) 94 (41.2%) 241 (34.9%)
College or university 84 (25.3%) 41 (31.3%) 102 (44.7%) 227 (32.8%)
Employed, n (%) 111 (32.7%) 43 (32.8%) 71 (31.0%) 225 (32.2%)
Living alone, n (%) 30 (8.8%) 36 (27.5%) 71 (33.0%) 137 (20.0%)
Presence of other pain condition, n (%) 96 (28.3%) 48 (36.6%) 114 (49.4%) 258 (36.8%)
Impaired immune status, n (%) 36 (10.6%) 21 (15.9%) 9 (3.9%) 66 (9.4%)
Herpes zoster characteristics
Primary dermatome region, n (%)
Thoracic 152 (45.0%) 53 (41.7%) 109 (49.3%) 314 (45.8%)
Trigeminal nerve 65 (19.2%) 10 (7.9%) 12 (5.4%) 87 (12.7%)
Cervical 67 (19.8%) 36 (28.3%) 42 (19.0%) 145 (21.1%)
Lumbar 39 (11.5%) 19 (15.0%) 43 (19.5%) 101 (14.7%)
Sacral 15 (4.4%) 9 (7.1%) 15 (6.8%) 39 (5.7%)
Severity of rash (number of lesions), n (%)
None or <20 (mild) 129 (38.1%) 84 (63.6%) 141 (61.3%) 354 (50.5%)
21–50 (moderate) 117 (34.5%) 28 (21.2%) 49 (21.3%) 194 (27.7%)
50 (severe) 93 (27.4%) 20 (15.2%) 40 (17.4%) 153 (21.8%)
Worst pain score at rash onset, n (%)
No/mild (0–2) 36 (10.7%) 9 (6.9%) 26 (11.5%) 71 (10.2%)
Moderate (3–6) 124 (36.8%) 21 (16.2%) 74 (32.6%) 219 (31.6%)
Severe (7) 177 (52.5%) 100 (76.9%) 127 (55.9%) 404 (58.2%)
Presence of prodromal pain, n (%) 227 (67.0%) 88 (67.2%) 175 (76.8%) 490 (70.2%)
Antiviral medications, n (%)
Aciclovir, valaciclovir, famciclovir 282 (83.2%) 118 (89.4%) 212 (91.8%) 612 (87.2%)
Did not receive 57 (16.8%) 14 (10.6%) 19 (8.2%) 90 (12.8%)
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and Latin America and Asia. Older age, greater severity of pain at rash
onset, employment status, walking problems at enrollment, and
pain interference affecting relationships with other people, were
identiﬁed as independent predictors of PHN.
Approximately 21% of patients aged 50 years developed PHN,
with the risk increasing with older age. The risk of PHN was almost
30% among patients aged 70 years. A number of prospective
cohort studies across countries have also noted a high risk of PHN,
ranging from approximately 10% to 30%, in elderly patients with
HZ.2,3,21,30 A population-based, retrospective cohort study in the
USA found that the risk of PHN (deﬁned as at least 90 days of
documented pain) was 10% in adults 60–69 years of age, 17% in
adults 70–79 years of age, and 20% in adults 80 years of age.2 The
generally higher estimate in the current analysis could be
explained by the fact that patients were followed prospectively
thus allowing a more accurate assessment of pain, or by differences
in the populations included. It is also possible that patients with
severe cases of HZ were more likely to have participated in the
present study.
It is well-recognized that a greater severity of acute pain at rash
onset is a risk factor for PHN (Table 4).8–23 Those who suffered from
severe pain most likely had a severe infection, resulting in
substantial neural damage. Consistent with prior studies, the
present study conﬁrmed that the severity of acute pain is a risk
factor for PHN. Biological and psychosocial factors are important in
understanding the pathophysiology of chronic pain.16,31 Thus, an
evaluation was done to determine whether pain-related interfer-
ence with diverse activities of daily living and living alone are
associated with an increased risk of the development of PHN. Itwas found that walking problems at enrollment and HZ pain
interference affecting relationships with other people remained
signiﬁcant predictors of PHN in the multivariate analysis. It was
also found that working adults, who are most likely healthy and
active, were less likely to develop PHN. Although few studies have
evaluated such factors, they have also suggested that impaired
physical and social functioning may play a role in the development
of PHN.16,20,23,32 Patients with predisposing vulnerabilities, possi-
bly with a reduced threshold of nociception as a result of genetic
factors or prior stressful life events, are more likely to be vulnerable
and suffer greatly from severe infection and develop PHN.31
Dworkin et al. and several other investigators have found that a
greater severity of rash is a risk factor for PHN.9,13,15,18,19 However,
the present study did not conﬁrm this association. Prospective
cohort studies with participants recruited from real-world
community settings (as opposed to participants in clinical trials)
have also shown the severity of rash not to be a risk factor for
PHN.14,17,23 It is possible that due to the wide recruitment window
in the present study (up to 14 days since rash onset), the rash in
some patients may have alleviated, which may have limited our
ability to observe such an association.
Other possible predictors of PHN were also evaluated. Several
studies have suggested that a severe or longer duration of
prodromal pain may increase the risk of developing PHN.8,11,15
In the present study, the presence of severe prodromal pain was
associated with an increased risk of PHN in the univariate analysis,
but it did not remain signiﬁcant after adjusting for severity of acute
pain and other factors in the multivariate analysis. Although a few
studies have suggested that female sex may be a risk factor, the
majority of prior studies and the present study found no difference
Table 2
Univariate analysis: predictors of postherpetic neuralgia among patients with herpes zoster
Predictors Developed PHN, n (%) Crude RR 95% CI p-Value
Region
Taiwan, South Korea, and Thailand 66 (19.5%) 0.80 (0.59, 1.10) 0.17
Mexico, Brazil, and Argentina 26 (19.7%) 0.81 (0.54, 1.23) 0.32
Canada 56 (24.2%) Reference
Age, years
50–59 37 (14.0%) Reference
60–69 45 (20.6%) 1.47 (0.99, 2.19) 0.055
70 65 (29.7%) 2.12 (1.48, 3.04) <0.001
Sex
Male 55 (20.4%) Reference
Female 93 (21.5%) 1.05 (0.78, 1.42) 0.73
Level of education
Primary/grade school 52 (23.3%) Reference
High school 51 (21.2%) 0.79 (0.55, 1.14) 0.21
College or university 42 (18.5%) 0.91 (0.65, 1.28) 0.58
Employment status
Yes 27 (12.0%) 0.47 (0.32, 0.69) <0.001
No 121 (25.5%) Reference
Living alone
Yes 35 (25.5%) 1.32 (0.95, 1.84) 0.10
No 106 (19.3%) Reference
Health conditions
Immune status
Impaired 13 (19.7%) 0.93 (0.56, 1.55) 0.77
Normal 135 (21.2%) Reference
Presence of other pain condition
Yes 56 (21.7%) 1.05 (0.78, 1.40) 0.77
No 92 (20.8%) Reference
Pre-existing problems in EQ-5D health domains before HZ (no problem as reference)
Walking 23 (26.4%) 1.29 (0.88, 1.90) 0.19
Self-care 9 (25.0%) 1.19 (0.66, 2.14) 0.56
Usual activities 17 (23.0%) 1.10 (0.71 1.72) 0.68
Having pain or discomfort 49 (23.8%) 1.18 (0.88, 1.60) 0.27
Being anxious or depressed 28 (17.7%) 0.80 (0.55, 1.16) 0.23
Herpes zoster characteristics
Severity of rash (number of lesions)
<20 (no/mild) 65 (18.4%) Reference
21–50 (moderate) 47 (24.2%) 1.32 (0.95, 1.84) 0.10
50 (severe) 36 (23.5%) 1.28 (0.89, 1.84) 0.18
Worst pain score at rash onset
No/mild (0–2) 4 (5.6%) Reference
Moderate (3–6) 33 (15.1%) 2.68 (0.98, 7.29) 0.054
Severe (7) 109 (27.0%) 4.79 (1.82, 12.58) 0.001
Duration of prodromal pain
None 38 (18.3%) Reference
1–2 days 25 (17.5%) 0.96 (0.61, 1.51) 0.85
3–4 days 41 (24.3%) 1.33 (0.90, 1.97) 0.16
5 days 40 (23.3%) 1.27 (0.86, 1.89) 0.23
Worst pain score for prodromal pain
No/mild (0–2) 39 (15.5%) Reference
Moderate (3–6) 39 (20.4%) 1.32 (0.88, 1.97) 0.18
Severe (7) 67 (27.1%) 1.75 (1.23, 2.50) 0.002
Problems in EQ-5D health domains at enrollment (no problem as reference)
Walking 62 (31.8%) 1.87 (1.41, 2.48) <0.001
Self-care 42 (32.8%) 1.77 (1.31, 2.39) <0.001
Usual activities 80 (27.8%) 1.69 (1.27, 2.25) <0.001
Having pain or discomfort 130 (23.4%) 1.91 (1.20, 3.06) 0.007
Being anxious or depressed 82 (23.6%) 1.27 (0.95, 1.69) 0.11
Pain interference at enrollment, reported 5 (<5 as reference)
General activity 91 (27.7%) 1.83 (1.36, 2.47) <0.001
Mood 86 (26.1%) 1.59 (1.18, 2.12) 0.002
Walking ability 50 (31.3%) 1.73 (1.29, 2.32) <0.001
Normal work 77 (27.4%) 1.64 (1.23, 2.19) 0.001
Relations with other people 65 (31.9%) 1.94 (1.46, 2.57) <0.001
Sleep 94 (26.0%) 1.65 (1.22, 2.23) 0.001
Enjoyment of life 85 (26.0%) 1.56 (1.17, 2.09) 0.003
Antiviral medications
Aciclovir, valaciclovir, famciclovir 133 (21.7%) 1.30 (0.80, 2.12) 0.28
Did not receive 15 (16.7%) Reference
Timely antiviral medications
Received within 72 h of rash onset 70 (18.6%) 1.61 (0.97, 2.67) 0.067
Received after 72 h of rash onset 63 (26.8%) 1.11 (0.67, 1.85) 0.68
Did not receive 15 (16.7%) Reference
PHN, postherpetic neuralgia; RR, relative risk; CI, conﬁdence interval; HZ, herpes zoster.
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Table 3
Multivariate analysis: predictors of postherpetic neuralgia among patients with
herpes zoster
Predictors Adjusted RR 95% CI p-Value
Age, years
50–59 Reference
60–69 1.20 (0.81, 1.79) 0.36
70 1.72 (1.18, 2.51) 0.005
Employment status
Yes 0.58 (0.38, 0.89) 0.012
No Reference
Worst pain score at rash onset
No/mild (0–2) Reference
Moderate (3–6) 2.46 (0.91, 6.66) 0.077
Severe (7) 3.58 (1.36, 9.45) 0.01
Walking problems at enrollment
Yes 1.47 (1.11, 1.93) 0.006
No Reference
Pain interference at enrollment, relations with other people
Yes 1.69 (1.27, 2.25) <0.001
No Reference
RR, relative risk; CI, conﬁdence interval.
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important to reduce the replication of the virus and the severity
and duration of pain during the acute phase. However, consistent
with a recent review, timely antiviral medication was not
associated with the incidence of PHN in the present study.33
Several limitations of this study are worth noting. Patients who
participated may not comprise a random sample of patients from
the general population, possibly limiting the generalizability of the
results. The type of pain was not characterized, which may have
allowed a better understanding of the pathophysiology of PHN.
Patients suffering from PHN experience different types of pain,
presumably because of different pathophysiological mechanisms
involving sensitization in the peripheral and central nervous
system, deafferentation, and possibly chronic inﬂammation.5,6Table 4
Prior studies examining predictors of postherpetic neuralgia (PHN)
References PHN deﬁnition R
Whitley et al.8 Prolonged HZ-associated pain N
Dworkin et al.9;
Nagasako et al.10
Pain persisting for 30 or 90 days 3
Decroix et al.11 Prolonged HZ-associated pain N
Haanpaa et al.12 Pain persisting for 90 days 2
Kurokawa et al.13 Pain persisting for 90 days N
Scott et al.14 Pain persisting for 90 days 2
Jung et al.15 Pain persisting for 120 days 1
Katz et al.16 Pain persisting for 120 days 2
Coen et al.17 Pain score 3 persisting for 90
or 180 days
9
Opstelten et al.18 Pain score 3 persisting for 90 days 8
Volpi et al.19 Pain score 3 persisting for 180 days 3
Drolet et al.20 Pain score 3 persisting for 90 days 2
Parruti et al.21 Pain persisting for 30 or 90 days 3
Kanbayashi et al.22 Pain persisting for 90 days 5
Bouhassira et al.23 Pain persisting for 90 days 1
NA, not available.This study has several strengths. The ﬁndings are based on a
methodologically robust, prospective cohort study using the same
questionnaires across countries. Prior research has rarely been
conducted in Latin America and Asia; thus, a multi-country study
including those regions was conducted. Multiple different deﬁni-
tions of PHN have been used previously. However, the validated
deﬁnition of PHN, which is a pain score of 3 (clinically meaningful
pain) lasting or appearing more than 90 days after rash onset, was
used in the present research.
In conclusion, the risk of developing PHN was over 20% in this
prospective cohort study of patients with HZ from North and Latin
America and Asia. It is conﬁrmed that older age and a greater
severity of pain at rash onset are risk factors for PHN. Additionally,
this study suggests that impaired physical and social functioning
from acute pain of HZ may also be risk factors for PHN. HZ patients
who are at greater risk of developing PHN should be monitored
closely for early treatment. Early prevention through vaccination
should be considered to reduce the risk of developing HZ and PHN.
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Outcomes – Vaccines.isk of PHN Predictors of PHN
A (n = 2367) Age, severity of acute pain, and presence of
prodromal pain
0% (n = 419) Age, severity of acute pain, severity of rash,
and antiviral treatment
A (n = 1897) Age, severity of acute pain, intensity of
prodromal pain, HZ ophthalmicus
5% (28/113) Age, severity of acute pain, and allodynia
A (n = 263) Age, severity of rash, disturbed sleep,
and hypaesthesia
7% (42/153) Age and severity of acute pain
2% (114/965) Age, female sex, severity of acute pain, severity
of rash, and presence of prodromal pain
0% (20/102) Age, severity of acute pain, and psychosocial
factors
.6% (24/250) Age and severity of acute pain
% (46/598) Age, severity of acute pain, severity of rash, and
duration of rash before consultation
2% (70/219) Age, severity of acute pain, severity of rash, and
longer duration of prodromal pain
2.5% (56/249) Age, severity of acute pain, and limitation in
performing usual activities
0% (130/441) Age, severity of acute pain, smoking, trauma,
and missed antiviral prescription
2% (38/73) Age and deep pain
1.6% (127/1091) Age, male sex, neuropathic quality of pain,
interference of pain on daily
activities, and physical component summary score
K. Kawai et al. / International Journal of Infectious Diseases 34 (2015) 126–131 131References
1. Cohen JI. Clinical practice: herpes zoster. N Engl J Med 2013;369:255–63.
2. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-
based study of the incidence and complication rates of herpes zoster before
zoster vaccine introduction. Mayo Clin Proc 2007;82:1341–9.
3. Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and
complications of herpes zoster: towards a global perspective. BMJ Open
2014;4:e004833.
4. Johnson RW, Bouhassira D, Kassianos G, Leple`ge A, Schmader KE, Weinke T. The
impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med
2010;8:37.
5. Johnson RW, Wasner G, Saddier P, Baron R. Postherpetic neuralgia: epidemiol-
ogy, pathophysiology and management. Expert Rev Neurother 2007;7:1581–95.
6. Schmader KE, Dworkin RH. Herpes zoster and postherpetic neuralgia. In: Benzon
HT, Raja SN, Liu SS, Fishman SM, Cohen SP, Hurley RW, et al., editors. Essentials of
pain medicine.. Third ed., Saint Louis: W.B. Saunders; 2011. p. 358–64.
7. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A
vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N
Engl J Med 2005;352:2271–84.
8. Whitley RJ, Shukla S, Crooks RJ. The identiﬁcation of risk factors associated with
persistent pain following herpes zoster. J Infect Dis 1998;178(Suppl 1):S71–5.
9. Dworkin RH, Boon RJ, Grifﬁn DR, Phung D. Postherpetic neuralgia: impact of
famciclovir, age, rash severity, and acute pain in herpes zoster patients. J Infect
Dis 1998;178(Suppl 1):S76–80.
10. Nagasako EM, Johnson RW, Grifﬁn DR, Dworkin RH. Rash severity in herpes
zoster: correlates and relationship to postherpetic neuralgia. J Am Acad Der-
matol 2002;46:834–9.
11. Decroix J, Partsch H, Gonzalez R, Mobacken H, Goh CL, Walsh L, et al. Factors
inﬂuencing pain outcome in herpes zoster: an observational study with vala-
ciclovir. Valaciclovir International Zoster Assessment Group (VIZA). J Eur Acad
Dermatol Venereol 2000;14:23–33.
12. Haanpaa M, Laippala P, Nurmikko T. Allodynia and pinprick hypesthesia in
acute herpes zoster, and the development of postherpetic neuralgia. J Pain
Symptom Manage 2000;20:50–8.
13. Kurokawa I, Kumano K, Murakawa K. Clinical correlates of prolonged pain in
Japanese patients with acute herpes zoster. J Int Med Res 2002;30:56–65.
14. Scott FT, Leedham-Green ME, Barrett-Muir WY, Hawrami K, Gallagher WJ,
Johnson R, et al. A study of shingles and the development of postherpetic
neuralgia in East London. J Med Virol 2003;70(Suppl 1):S24–30.
15. Jung BF, Johnson RW, Grifﬁn DR, Dworkin RH. Risk factors for postherpetic
neuralgia in patients with herpes zoster. Neurology 2004;62:1545–51.
16. Katz J, McDermott MP, Cooper EM, Walther RR, Sweeney EW, Dworkin RH.
Psychosocial risk factors for postherpetic neuralgia: a prospective study of
patients with herpes zoster. J Pain 2005;6:782–90.
17. Coen PG, Scott F, Leedham-Green M, Nia T, Jamil A, Johnson RW, et al. Predicting
and preventing post-herpetic neuralgia: are current risk factors useful in
clinical practice? Eur J Pain 2006;10:695–700.
18. Opstelten W, Zuithoff NP, van Essen GA, van Loon AM, van Wijck AJ, Kalkman CJ,
et al. Predicting postherpetic neuralgia in elderly primary care patients with
herpes zoster: prospective prognostic study. Pain 2007;132(Suppl 1):S52–9.19. Volpi A, Gatti A, Pica F, Bellino S, Marsella LT, Sabato AF. Clinical and
psychosocial correlates of post-herpetic neuralgia. J Med Virol 2008;80:
1646–52.
20. Drolet M, Brisson M, Schmader K, Levin M, Johnson R, Oxman M, et al. Predictors
of postherpetic neuralgia among patients with herpes zoster: a prospective
study. J Pain 2010;11:1211–21.
21. Parruti G, Tontodonati M, Rebuzzi C, Polilli E, Sozio F, Consorte A, et al.
Predictors of pain intensity and persistence in a prospective Italian cohort of
patients with herpes zoster: relevance of smoking, trauma and antiviral thera-
py. BMC Med 2010;8:58.
22. Kanbayashi Y, Onishi K, Fukazawa K, Okamoto K, Ueno H, Takagi T, et al.
Predictive factors for postherpetic neuralgia using ordered logistic regression
analysis. Clin J Pain 2012;28:712–4.
23. Bouhassira D, Chassany O, Gaillat J, Hanslik T, Launay O, Mann C, et al. Patient
perspective on herpes zoster and its complications: an observational prospec-
tive study in patients aged over 50 years in general practice. Pain 2012;153:
342–9.
24. Drolet M, Brisson M, Levin MJ, Schmader KE, Oxman MN, Johnson RW, et al. A
prospective study of the herpes zoster severity of illness. Clin J Pain 2010;26:
656–66.
25. Aunhachoke K, Bussaratid V, Chirachanakul P, Chua-Intra B, Dhitavat J, Jai-
sathaporn K, et al. Measuring herpes zoster, zoster-associated pain, post-
herpetic neuralgia-associated loss of quality of life, and healthcare utilization
and costs in Thailand. Int J Dermatol 2011;50:428–35.
26. Song H, Lee J, Lee M, Choi WS, Choi JH, Lee MS, et al. Burden of illness, quality of
life, and healthcare utilization among patients with herpes zoster in South
Korea: a prospective clinical–epidemiological study. Int J Infect Dis 2014;20:
23–30.
27. Vujacich C, De Wouters L, Margari A, Gordovil M, Kawai K, Lemos E, et al.
Assessment of burden of illness due to herpes zoster in Argentina: a prospective
observational study. Value in Health 2013;16:A668 [Epub ahead of print].
28. Tsai TF, Yao CA, Yu HS, Lan CC, Chao SC, Yang JH, et al. Herpes zoster-
associated severity and duration of pain, health-related quality of life, and
healthcare utilization in Taiwan: a prospective observational study. Int J
Dermatol 2014.
29. Coplan PM, Schmader K, Nikas A, Chan IS, Choo P, Levin MJ, et al. Development
of a measure of the burden of pain due to herpes zoster and postherpetic
neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain
2004;5:344–56.
30. Gauthier A, Breuer J, Carrington D, Martin M, Re´my V. Epidemiology and cost of
herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol
Infect 2009;137:38–47.
31. Dworkin RH, Banks SM. A vulnerability–diathesis–stress model of chronic pain:
herpes zoster and the development of postherpetic neuralgia. In: Gatchel RJ,
Turk DC, editors. Psychosocial factors in pain: critical perspectives.. The Guilford
Press; 1999.
32. Haythornthwaite JA, Clark MR, Pappagallo M, Raja SN. Pain coping strategies
play a role in the persistence of pain in post-herpetic neuralgia. Pain
2003;106:453–60.
33. Chen N, Li Q, Yang J, Zhou M, Zhou D, He L. Antiviral treatment for preventing
postherpetic neuralgia. Cochrane Database Syst Rev 2014;2:CD006866.
